Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands.
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Int J Food Microbiol. 2015 Mar 2;196:84-93. doi: 10.1016/j.ijfoodmicro.2014.11.022. Epub 2014 Dec 3.
To inform risk management decisions on control and prevention of food-related disease, both the disease burden expressed in Disability Adjusted Life Years (DALY) and the cost-of-illness of food-related pathogens are estimated and presented. Disease burden of fourteen pathogens that can be transmitted by food, the environment, animals and humans was previously estimated by Havelaar et al. (2012). In this paper we complement these by cost-of-illness estimates. Together, these present a complete picture of the societal burden of food-related diseases. Using incidence estimates for 2011, community-acquired non-consulting cases, patients consulting their general practitioner, hospitalized patients and the incidence of sequelae and fatal cases, estimates were obtained for DALYs, direct healthcare costs (e.g. costs for doctor's fees, hospitalizations and medicines), direct non-healthcare costs (e.g. travel costs to and from the doctor), indirect non-healthcare costs (e.g. productivity loss, special education) and total costs. The updated disease burden for 2011 was equal to 13,940 DALY/year (undiscounted) or 12,650 DALY/year (discounted at 1.5%), and was of the same magnitude as previous estimates. At the population-level thermophilic Campylobacter spp., Toxoplasma gondii and rotavirus were associated with the highest disease burden. Perinatal listeriosis infection was associated with the highest DALY per symptomatic case. The total cost-of-illness in 2011 of fourteen food-related pathogens and associated sequelae was estimated at € 468 million/year, if undiscounted, and at € 416 million/year if discounted by 4%. Direct healthcare costs accounted for 24% of total costs, direct non-healthcare costs for 2% and indirect non-healthcare costs for 74% of total costs. At the population-level, norovirus had the highest total cost-of-illness in 2011 with € 106 million/year, followed by thermophilic Campylobacter spp. (€ 76 million/year) and rotavirus (€ 73 million/year). Cost-of-illness per infected case varied from € 150 for Clostridium perfringens intoxications to € 275,000 for perinatal listeriosis. Both incident cases and fatal cases are more strongly correlated with COI/year than with DALY/year. More than 40% of all cost-of-illness and DALYs can be attributed to food, in total € 168 million/year and 5,150 DALY/year for 2011. Beef, lamb, pork and poultry meat alone accounted for 39% of these costs. Products of animal origin accounted for € 86 million/year (or 51% of the costs attributed to food) and 3,320 DALY/year (or 64% of the disease burden attributed to food). Among the pathogens studied Staphylococcus aureus intoxications accounted for the highest share of costs attributed to food (€ 47.1 million/year), followed by Campylobacter spp. (€ 32.0 million/year) and norovirus (€ 17.7 million/year).
为了在食品相关疾病的控制和预防方面做出风险管理决策,我们对食品相关病原体的疾病负担(以残疾调整生命年(DALY)表示)和疾病成本进行了评估并呈现。哈维拉尔等人(2012 年)曾对可通过食物、环境、动物和人类传播的 14 种病原体的疾病负担进行了评估。在本文中,我们通过疾病成本评估对其进行了补充。这些一起构成了食品相关疾病的社会负担的全貌。使用 2011 年的发病率估计数、社区获得性非咨询病例、向全科医生就诊的患者、住院患者以及后遗症和死亡病例的发病率,我们获得了 DALY、直接医疗保健费用(例如医生费用、住院和药物费用)、直接非医疗保健费用(例如往返医生的旅行费用)、间接非医疗保健费用(例如生产力损失、特殊教育)和总费用的估计数。2011 年更新的疾病负担相当于每年 13940 DALY(未贴现)或每年 12650 DALY(贴现率为 1.5%),与之前的估计值相同。在人群水平上,嗜热弯曲杆菌、刚地弓形虫和轮状病毒与最高的疾病负担相关。围产期李斯特菌感染与每例有症状病例的最高 DALY 相关。2011 年 14 种食品相关病原体及其相关后遗症的总成本估计为 4.68 亿欧元/年(未贴现),如果贴现 4%,则为 4.16 亿欧元/年。直接医疗保健费用占总成本的 24%,直接非医疗保健费用占 2%,间接非医疗保健费用占总成本的 74%。在人群水平上,2011 年诺如病毒的总疾病成本最高,为 1.06 亿欧元/年,其次是嗜热弯曲杆菌(7600 万欧元/年)和轮状病毒(7300 万欧元/年)。每例感染病例的疾病成本从产气荚膜梭菌中毒的 150 欧元到围产期李斯特菌病的 27.5 万欧元不等。发病病例和死亡病例与 COI/年的相关性强于与 DALY/年的相关性。超过 40%的所有疾病成本和 DALY 都可归因于食品,2011 年为 1.68 亿欧元/年和 5150 DALY/年。仅牛肉、羊肉、猪肉和禽肉就占这些成本的 39%。动物源产品占 8600 万欧元/年(占归因于食品的成本的 51%)和 3320 DALY/年(占归因于食品的疾病负担的 64%)。在所研究的病原体中,金黄色葡萄球菌中毒导致的归因于食品的费用最高(4710 万欧元/年),其次是弯曲杆菌(3200 万欧元/年)和诺如病毒(1770 万欧元/年)。